ZJYL
Jin Medical·NASDAQ
--
--(--)
--
--(--)
1.03 / 10
Underperform
Analysis concludes inadequate fundamental quality (1.0/10). Favorable components: ROA (%) and Annualized net profit margin on total assets (%), balanced by issues in Net profit / Total profit (%). Investment recommendation: guarded.
Analysis Checks(4/5)
ROA (%)
Value0.02
Score3/3
Weight-31.83%
1M Return1.03%
Value0.02
Score3/3
Weight-31.83%
1M Return1.03%
Annualized net profit margin on total assets (%)
Value0.04
Score3/3
Weight-31.83%
1M Return1.03%
Value0.04
Score3/3
Weight-31.83%
1M Return1.03%
Net profit / Total profit (%)
Value31.50
Score1/3
Weight68.44%
1M Return-2.89%
Value31.50
Score1/3
Weight68.44%
1M Return-2.89%
Net profit attributable to parent company shareholders / Net profit (%)
Value-989.20
Score2/3
Weight44.76%
1M Return-1.71%
Value-989.20
Score2/3
Weight44.76%
1M Return-1.71%
Interest coverage ratio (EBIT / Interest expense) (%)
Value27.58
Score2/3
Weight50.46%
1M Return-1.95%
Value27.58
Score2/3
Weight50.46%
1M Return-1.95%
ROA (%)
Value0.02
Score3/3
Weight-31.83%
1M Return1.03%
Value0.02
Score3/3
Weight-31.83%
1M Return1.03%
Net profit attributable to parent company shareholders / Net profit (%)
Value-989.20
Score2/3
Weight44.76%
1M Return-1.71%
Value-989.20
Score2/3
Weight44.76%
1M Return-1.71%
Annualized net profit margin on total assets (%)
Value0.04
Score3/3
Weight-31.83%
1M Return1.03%
Value0.04
Score3/3
Weight-31.83%
1M Return1.03%
Interest coverage ratio (EBIT / Interest expense) (%)
Value27.58
Score2/3
Weight50.46%
1M Return-1.95%
Value27.58
Score2/3
Weight50.46%
1M Return-1.95%
Net profit / Total profit (%)
Value31.50
Score1/3
Weight68.44%
1M Return-2.89%
Value31.50
Score1/3
Weight68.44%
1M Return-2.89%
Is ZJYL fundamentally strong?
- ZJYL scores 1.03/10 on fundamentals and holds a Premium valuation at present. Backed by its -0.32% ROE, 7.55% net margin, 12.14 P/E ratio, 0.78 P/B ratio, and -50.00% earnings growth, these metrics solidify its Underperform investment rating.
